Named after Thomas Edison, the Edison Awards recognize and honor the most innovative products and leaders in the world.

n-Lorem wins gold in the Treatment Optimization category based on its industrialized process that embeds quality in every step to provide individualized experimental ASOs to nano-rare patients.

n-Lorem, a nonprofit Foundation, today announced that it has been selected as a 2023 Edison gold award winner in the Treatment Optimization category for Health, Medical, and Biotech. This award recognizes n-Lorem’s innovative, non-profit approach to discover, develop and provide individualized, experimental ASO medicines for nano-rare patients (1 to 30 patients with the same single gene mutation worldwide) for free for life.

“n-Lorem is pleased to be recognized alongside such a prestigious group of innovative organizations that are making a positive impact on the daily lives of patients around the world. What we are doing at n-Lorem for nano-rare patients is truly extraordinary and unique. Our mission is to provide hope and potential help to nano-rare patients today for free, for life,” said Stanley T. Crooke, M.D., Ph.D., Founder, Chairman and CEO of n-Lorem Foundation. “We believe that every nano-rare patient deserves the very best ASO that we can discover and develop. At n-Lorem we have the expertise, knowledge, automation and experience to discover optimal ASOs for our patients even as we scale up to meet a growing demand from the nano-rare community. Already we have accepted more than 90 patients into our program and expect this number to continue to increase as more patients are treated and more patients find their way to n-Lorem.”

The Edison Awards honor excellence in new product and service development, marketing, human-centered design and innovation. In its 36th year, the annual competition is among the most prestigious accolades not only recognizing world-changing innovations, but also the brilliant minds behind them. Previous winners include Moderna, Merck, and Steve Jobs. The Edison Awards are inspired by Thomas A. Edison (1847-1931), an American icon with an international presence. His extraordinary new product and market development methods earned him 1,093 U.S. patents.

Learn more about the exciting progress n-Lorem has made by reading Stan Crooke’s annual letter and visit n-Lorem’s new website.

• Read: 2023 Annual Letter (Part 1)

Learn more about n-Lorem’s mission at www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these needy patients and families.

• Subscribe: n-Lorem Patient Empowerment Program Podcast Series
• Watch: n-Lorem Foundation Delivers Hope and Treatment for Patient with Nano-Rare Disease
• Watch: n-Lorem Foundation: Creating a Better Future for Nano-Rare, One Patient at a Time

About n-Lorem

n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem has assisted in the development and treatment of 14 nano-rare patients and received over 190 applications for treatment with more than 90 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow us on Twitter, Facebook, LinkedIn and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005473/en/